Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02191488 · ClinicalTrials.gov registry record · Phase 1
ALA-induced PpIX Fluorescence During Brain Tumor Resection
A Phase 1 study of Brain Tumors, sponsored by David W. Roberts.
- Active
- Registry status
- Phase 1
- Development phase
- 540
- Enrollment target
- 1
- Study location
NCT02191488: Active Phase 1 study of Brain Tumors, sponsored by David W. Roberts.
NCT02191488 is a Phase 1 study of Brain Tumors that is active but no longer recruiting, run by David W. Roberts. The registered enrollment target is 540 participants, below the 6,289-participant average among 10 other Brain Tumors trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02191488, a Phase 1 study of Brain Tumors, is active but no longer recruiting, sponsored by David W. Roberts.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 540 participants
- Enrollment target
- 1
- Study location
Study Summary
Removing a tumor from a patients brain is hard to do because, very often, brain tumors do not have boundaries that are easy for the patients surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends. The surgeon usually can remove most of the patient's tumor by looking at the MRI images that were taken of the patient's brain before surgery. However, the surgeon does not have any good way to tell if the entire tumor has been removed or not. Removing the entire tumor is very important because leaving tumor behind may allow it to grow back which could decrease the chances of survival.
Primary Outcome
To estimate the probability of tumor distribution for a given PpIX concentration by comparing intraoperative measurements with coregistered histopathology obtained from biopsy sampling during the procedure
Conditions Studied
Interventions
- DRUG 5-aminolevulinic acid
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2014-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT02191488 still lists
NCT02191488 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 6,289-participant average among 10 other Brain Tumors trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Brain Tumors appearing as the primary indexed condition, and to 1 intervention - of which 5-aminolevulinic acid is the first listed.
NCT02191488 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT02191488 about?
NCT02191488 is a clinical study titled "ALA-induced PpIX Fluorescence During Brain Tumor Resection". Removing a tumor from a patients brain is hard to do because, very often, brain tumors do not have boundaries that are easy for the patients surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends. The surgeon usually can remove most of the patient's tumor by lo...
What is the current status of trial NCT02191488?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 540 participants. The study started on 2014-07. Estimated completion is 2026-12-31.
What conditions does trial NCT02191488 study?
This clinical trial studies the following conditions: Brain Tumors.
What interventions are being tested in trial NCT02191488?
The interventions under investigation include: 5-aminolevulinic acid (DRUG).
Who is sponsoring clinical trial NCT02191488?
This trial is sponsored by David W. Roberts, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02191488 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02191488's enrollment target sits among peer trials
540 4th of 10 higher than 7 of 10 other Brain Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
COMPLETED · Phase 1
-
Nicardipine vs Esmolol Craniotomy Emergence
COMPLETED · Phase 1
-
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
COMPLETED · Phase 1
-
Florida Center for Brain Tumor Research
RECRUITING
-
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
ACTIVE NOT RECRUITING
-
Blood Flow MRI for Monitoring Brain Tumors
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia